Lyka Labs Limited
LYKALABS · NSE · Healthcare
StocksWizard rates Lyka Labs Limited a Sell, scoring 42/100 on our blended model. At ₹67.38 it trades below our blended DCF and relative-multiples fair value of ₹123.83, implying roughly 84% upside to that estimate — we read the stock as undervalued by 84%. It clears 3 of 7 investability checks, with durability 0, valuation 49 and momentum 55 on our 0–100 scales.
These are StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹99.07. Low-confidence estimate — limited data.
Piotroski F-score 2/9 — quality of earnings & balance sheet.
Investability checklist
- –ROE above 15%
- –Low debt (D/E < 0.5)
- ✕Positive free cash flow
- –Revenue growth > 10%
- –Earnings growing
- ✕Net margin ≥ 10%-0.5%
- –Current ratio > 1.5
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- –Altman Z in safe zone
- ✕Piotroski ≥ 72/9
1-year price
EOD · 2026-06-19Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Weaknesses
- •Price below its 200-day moving average (downtrend).
- •Weak Piotroski score (2/9).
Opportunities
- •Well off its 52-week high — possible mean-reversion.
- •Trades ~84% below our estimated fair value.
About Lyka Labs Limited
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant tablets and c
More in Healthcare
All stocksOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.